Recent Developments on Coronavirus Main Protease/3C Like Protease Inhibitors

ISSN: 2212-4071 (Online)
ISSN: 1574-891X (Print)

Volume 10, 2 Issues, 2015

Download PDF Flyer

Recent Patents on Anti-Infective Drug Discovery

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Dieter Kabelitz
Institute of Immunology
Universitätsklinikum Schleswig-Holstein
Campus Kiel
Arnold-Heller-Straße 3
Kiel, D-24105

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Recent Developments on Coronavirus Main Protease/3C Like Protease Inhibitors

Recent Patents on Anti-Infective Drug Discovery, 8(2): 150-156.

Author(s): Qi Zhao, Erin Weber and Haitao Yang.

Affiliation: Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520, USA.


Coronaviruses have been thrust into the spotlight by the recurring novel human coronavirus infections following the 2003 SARS pandemic. In the years since the initial SARS outbreak, the arsenal to fight this virus family has been significantly increased by the rapid growth of coronavirus research. Among the potential viral drug targets, coronavirus 3C like proteases (3Cl) have emerged as the most popular drug target. A number of patented inhibitors with promising clinical potential have been developed via different methods of drug discovery, including virtual screening, natural product isolation and structure assisted rational drug design. This review serves as a summary of the progress in both the method of drug discovery and the related inhibitors against the coronavirus 3Cl protease.


Antiviral, 3C like proteases, coronavirus, inhibitor, main protease, natural product, rational drug design, virtual screening.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 2
First Page: 150
Last Page: 156
Page Count: 7
DOI: 10.2174/1574891X113089990017

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science